Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Feb;7(1):26-30.
doi: 10.1177/1759720X14554793.

Rituximab and its therapeutic potential in catastrophic antiphospolipid syndrome

Ignasi Rodríguez-Pintó  1 , Ricard Cervera  1 , Gerard Espinosa  2
Affiliations
Review

Rituximab and its therapeutic potential in catastrophic antiphospolipid syndrome

Ignasi Rodríguez-Pintó et al. Ther Adv Musculoskelet Dis. 2015 Feb.

Abstract

The catastrophic antiphospholipid syndrome (CAPS) is characterized by thrombosis in more than three organs or systems developing over a short period of time. Despite conventional treatment with a combination of anticoagulation plus corticosteroids plus plasma exchange, and/or intravenous immunoglobulin, mortality remains high and some patients suffer from recurrent CAPS episodes. In selected patients, new therapies such as rituximab may be a treatment option. In this review, the rationale for using rituximab in CAPS is discussed.

Keywords: anti-CD20; catastrophic antiphospholipid syndrome; refractory; rituximab.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declare no conflict of interest in preparing this article.

References

    1. Asherson R. (1992) The catastrophic antiphospholipid syndrome. J Rheumatol 19: 508–512. - PubMed
    1. Asherson R., Cervera R., De Groot P., Erkan D., Boffa M., Piette J., et al. (2003) Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12: 530–534. - PubMed
    1. Berman H., Rodríguez-Pintó I., Cervera R., Morel N., Costedoat-Chalumeau N., Erkan D., et al. (2013) Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev 12: 1085–1090. - PubMed
    1. Bucciarelli S., Espinosa G., Cervera R., Erkan D., Gómez-Puerta J., Ramos-Casals M., et al. (2006) Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum 54: 2568–2576. - PubMed
    1. Buch M., Smolen J., Betteridge N., Breedveld F., Burmester G., Dörner T., et al. (2011) Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 70: 909–920. - PMC - PubMed

LinkOut - more resources